In this cohort, PD-L1 expression on immune cells (IC) was assessed by the SP142 assay, which is identical to the assay used in our 149 TNBCs, though the urothelial carcinoma cohort was score as IC0 (< 1%), IC1 (≥ 1% and < 5%), or IC2/3 (≥ 5%). Here, CD274 is linked to urothelial carcinoma.